253 related articles for article (PubMed ID: 17909310)
1. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
LeWitt PA
Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
[No Abstract] [Full Text] [Related]
2. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
3. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
4. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
5. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
6. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
7. Selegiline HC1: Selective MAO-type B inhibitor.
Koller WC; Giron LT
Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
[No Abstract] [Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
9. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
[TBL] [Abstract][Full Text] [Related]
10. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.
Ito D; Amano T; Sato H; Fukuuchi Y
J Neurol; 2001 Jun; 248(6):533-4. PubMed ID: 11499649
[No Abstract] [Full Text] [Related]
11. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
12. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
13. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O
Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
[No Abstract] [Full Text] [Related]
15. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Li XM; Juorio AV; Paterson IA; Boulton AA
J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
[No Abstract] [Full Text] [Related]
16. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Jansen Steur EN; Ballering LA
Adv Neurol; 1999; 80():505-8. PubMed ID: 10410764
[No Abstract] [Full Text] [Related]
17. Selegiline, pregnancy, and Parkinson's disease.
Kupsch A; Oertel WH
Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
[No Abstract] [Full Text] [Related]
18. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
[No Abstract] [Full Text] [Related]
19. A hypertensive reaction induced by concurrent use of selegiline and dopamine.
Rose LM; Ohlinger MJ; Mauro VF
Ann Pharmacother; 2000 Sep; 34(9):1020-4. PubMed ID: 10981248
[TBL] [Abstract][Full Text] [Related]
20. Critical role of MAO inhibition in Parkinson's disease.
Knoll J
Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
